ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
In the past year ORGO had a positive cash flow from operations.
ORGO had positive earnings in 4 of the past 5 years.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -4.37%, ORGO belongs to the best of the industry, outperforming 87.61% of the companies in the same industry.
Looking at the Return On Equity, with a value of -5.55%, ORGO belongs to the top of the industry, outperforming 89.95% of the companies in the same industry.
ORGO has a better Return On Invested Capital (1.02%) than 91.92% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO has a better Operating Margin (1.13%) than 92.10% of its industry peers.
In the last couple of years the Operating Margin of ORGO has declined.
Looking at the Gross Margin, with a value of 75.85%, ORGO belongs to the top of the industry, outperforming 83.66% of the companies in the same industry.
ORGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
ORGO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
ORGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.62 indicates that ORGO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.62, ORGO is in the better half of the industry, outperforming 76.30% of the companies in the same industry.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ORGO's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ORGO outperforms 47.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.62 |
ROIC/WACC0.1
WACC9.98%
2.3 Liquidity
ORGO has a Current Ratio of 4.12. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Current ratio (4.12) which is in line with its industry peers.
A Quick Ratio of 3.67 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Quick ratio (3.67) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.00%, which is quite impressive.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
Looking at the last year, ORGO shows a small growth in Revenue. The Revenue has grown by 5.36% in the last year.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 31.62% on average per year.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 10.53% on average per year.
EPS Next Y-61%
EPS Next 2Y16.19%
EPS Next 3Y31.62%
EPS Next 5YN/A
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 47.22 indicates a quite expensive valuation of ORGO.
Based on the Price/Earnings ratio, ORGO is valued cheaply inside the industry as 92.28% of the companies are valued more expensively.
ORGO's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.45.
With a Price/Forward Earnings ratio of 18.52, ORGO is valued on the expensive side.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 93.36% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, ORGO is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.22 | ||
| Fwd PE | 18.52 |
4.2 Price Multiples
ORGO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ORGO is cheaper than 94.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.12 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 31.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.19%
EPS Next 3Y31.62%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.25
+0.2 (+4.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.78%
Inst Owner Change-71.43%
Ins Owners31.29%
Ins Owner Change1.49%
Market Cap539.11M
Analysts84.44
Price Target6.38 (50.12%)
Short Float %15.91%
Short Ratio7.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)4.17%
PT rev (3m)4.17%
EPS NQ rev (1m)-66.67%
EPS NQ rev (3m)-400%
EPS NY rev (1m)73.33%
EPS NY rev (3m)23.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.22 | ||
| Fwd PE | 18.52 | ||
| P/S | 1.18 | ||
| P/FCF | N/A | ||
| P/OCF | 121.56 | ||
| P/B | 1.46 | ||
| P/tB | 1.65 | ||
| EV/EBITDA | 19.12 |
EPS(TTM)0.09
EY2.12%
EPS(NY)0.23
Fwd EY5.4%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY0.82%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 4.62 |
F-Score6
WACC9.98%
ROIC/WACC0.1
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-61%
EPS Next 2Y16.19%
EPS Next 3Y31.62%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A